Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosun licenses novel TB treatment for China

This article was originally published in Scrip

Executive Summary

Shanghai-based, Hong Kong and Shanghai listed Fosun Pharmaceutical has been busy adding foreign assets under its belt.

You may also be interested in...



FDA nod for first 'made in China' MAb

China is known for a global supplier of active pharmaceutical ingredients, but with continuous investment in advanced facilities and talents, it is likely to be a global supplier of biological therapies. The US approval of a 'made in China' monoclonal antibody for use in clinical trials marks a milestone in China's journey.

China's state council demands raised quality for "essential drugs"

Officials at the highest level of China's government have said that the quality of medicines on China's essential drugs list must be raised to international standards, a move that challenges the existing essential drugs scheme in the country1.

China’s state council demands raised quality for ‘essential drugs’

Officials at the highest level of China’s government have said that the quality of medicines on China’s essential drugs list must be raised to international standards, a move that challenges the existing essential drugs scheme in the country.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel